Catridecacog: Difference between revisions
Created page with "'''Catridecacog''' (brand name ''Tretten'') is a class of recombinant factor XIII A-subunit based medication, indicated in patients with a rare clottin..." |
m Protected "Catridecacog": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
== Overview == | |||
'''Catridecacog''' (brand name ''Tretten'') is a class of [[Recombinant DNA|recombinant]] [[factor XIII]] A-subunit based medication, indicated in patients with a rare clotting disorder, [[congenital factor XIII A-subunit deficiency]]. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. [[Food and Drug Administration]] (FDA) for this use in the US in 2014. | '''Catridecacog''' (brand name ''Tretten'') is a class of [[Recombinant DNA|recombinant]] [[factor XIII]] A-subunit based medication, indicated in patients with a rare clotting disorder, [[congenital factor XIII A-subunit deficiency]]. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. [[Food and Drug Administration]] (FDA) for this use in the US in 2014. | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
[http://www.pharmacist.com/catridecacog-first-drug-treat-rare-genetic-blood-clotting-disorder] | [http://www.pharmacist.com/catridecacog-first-drug-treat-rare-genetic-blood-clotting-disorder] | ||
| Line 10: | Line 17: | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
[[Category: | [[Category:Drug]] | ||
Latest revision as of 18:43, 18 August 2015
|
WikiDoc Resources for Catridecacog |
|
Articles |
|---|
|
Most recent articles on Catridecacog Most cited articles on Catridecacog |
|
Media |
|
Powerpoint slides on Catridecacog |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Catridecacog at Clinical Trials.gov Clinical Trials on Catridecacog at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Catridecacog
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Catridecacog Discussion groups on Catridecacog Patient Handouts on Catridecacog Directions to Hospitals Treating Catridecacog Risk calculators and risk factors for Catridecacog
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Catridecacog |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Catridecacog (brand name Tretten) is a class of recombinant factor XIII A-subunit based medication, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.
References